Biocryst Pharmaceuticals (BCRX) Net Equity Issued and Repurchased (2012 - 2021)

Biocryst Pharmaceuticals (BCRX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $50.0 million in Q4 2021.

• Quarterly Net Equity Issued and Repurchased rose 11500.93% year-over-year to $50.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $50.4 million (down 14.42% YoY) and the FY2021 annual result came in at $50.0 million, down 46.4% from the prior year.
• Net Equity Issued and Repurchased grew to $50.0 million in Q4 2021, from $431000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $86.2 million in Q3 2017 to a low of $431000.0 in Q4 2020.
• A 4-year average of $40.6 million and a median of $48.9 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased plunged 99.26% — and 2021, when it jumped 11500.93%.
• Tracing BCRX's Net Equity Issued and Repurchased over 4 years: stood at $500000.0 in 2017, then jumped by 11600.0% to $58.5 million in 2019, then sank by 99.26% to $431000.0 in 2020, then jumped by 11500.93% to $50.0 million in 2021.
• The last three Net Equity Issued and Repurchased figures came in at $50.0 million (Q4 2021), $431000.0 (Q4 2020), and $58.5 million (Q4 2019), per Business Quant data.